Xinhua Zhu, MD, PhD

Assistant Investigator, Patient Oriented Reseaerch/Karches Center for Oncology Research,
The Feinstein Institute for Medical Research

Attending Physician, Monter Cancer Center, Hematology and Oncology,
Department of Medicine, Northwell Health

Assistant Professor, Hofstra Northwell School of Medicine

Phone: (516) 734-8898
Email: xzhu1@northwell.edu

About the Investigator
Dr. Zhu is a physician scientist with an MD and PhD, Division of Medical Oncology and Hematology, at Northwell Health. His clinical practice is dedicated to the treatment of Genitourinary and Gastrointestinal malignancies, including kidney cancer, bladder cancer, prostate cancer and testicular cancer; esophageal cancer, gastric cancer, pancreatic cancer, hepatocellular carcinoma, gallbladder cancer, colorectal cancer and anal cancer. Dr. Zhu is board certified in internal medicine, hematology and medical oncology. He received his medical degree from Suzhou Medical College, completed his residency in Internal Medicine at Mount Sinai Medical Center Bronx Program and served as a Hematology and Medical Oncology Fellow at New York University Langone Medical Center.

Dr. Zhu is an active member of AACR, ASCO and ASH. He has authored or co-authored more than 20 original research papers and is Assistant Professor of Medicine at the Hofstra Northwell School of Medicine.

Research Focus
Identifying molecular biomarkers of cisplatin-based chemosensitivity for muscle-invasive bladder cancer; Identifying Novel Targets for Prostate Cancer Therapy; A Phase I Study of the Safety and Tolerability of Single Agent MSI-1436C in Metastatic Breast Cancer Patients; A Phase II Trial of a CDK4/6 Inhibitor, Ribociclib, in Patients with Metastatic or Unresectable pancreatic ductal adcenocarcinoma with p16, cyclin D and CDK4/6 alterations and intact Rb phosphorylation; The clinical outcome of abiraterone and enzalutamide in patients with metastatic castration resistant prostate cancer post-CHAARTED era.

Lab Members

Paras Shah
Jaspreet Chahal
Natasha Garg

Education

New York University Langone Medical Center
Degree: Fellowship
2013
Field of Study: Hematology and Oncology

Mount Sinai Medical Center Bronx Program
Degree: Residency
2010
Field of Study: Medicine

Memorial Sloan Kettering Cancer Center
Degree: Postdoctoral
2007
Field of Study: Regulation mechanism of p21 and p27 mediated by proteosome degradation

Shanghai Second Medical University
Degree: PhD
1999
Field of Study: Role of fusion genes in the leukemogenesis of acute promyelocytic leukemia and response to all trans-retinoic acid

Suzhou Medical College
Degree: MD
1987
Field of Study: Medicine

Honors and Awards

2015-2016 Teacher of the year,Hematology Oncology Fellow Education and Training Award
1999 First Prize Award,Shanghai Second Med University

Publications
  1. Staverosky J, Zhu XH, Ha S, Logan S. “Anti-androgen resistance in prostate cancer cells chronically induced by interleukin-1β.” Am J Clin Exp Urol 2013 Dec 30; 1(1): 53-65
  2. Ciznadija D, Zhu XH, Koff A. “Hdm2- and proteasome-dependent turnover limits p21 accumulation during S phase.” Cell Cycle  2011 Aug 15;10(16):2714-23.
  3. Liu Y, Yeh N, Zhu XH, Holland E, Koff A. “Somatic cell type specific gene transfer reveals a tumor-promoting function for p21 (Waf1/Cip1).” EMBO J 2007 Nov 14; 26(22):4683-93
  4. Liu Y, Hedvat CV, Mao S, Zhu XH, Yao J, Nguyen H, Koff A, Nimer SD. “The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2.” Mol Cell Biol 2006 Apr; 26(8):3114-23
  5. Zhu XH, Nguyen H, Halicka HD, Traganos F, Koff A. “Noncatalytic requirement for cyclin A-cdk2 in p27 turnover.” Mol Cell Biol 2004 Jul; 24 (13): 6058-6066
  6. Mo L, Zhu XH, Huang HY. “Ablation of Tamm-Horsfall Gene Increases the Susceptibility of Mice to Bladder Colonization by Type 1-fimbriated Escherichia coli.” Am J Physiol Renal Physiol  2004 Apr; 286 (4): F795-F802
  7. Zhu XH, Cheng J, Huang LW. “Renal tubule-specific expression and urinary secretion of human growth hormone: A kidney-based transgenic bioreactor.” Transgenic Research 2003 Apr; 12 (2): 155-162
  8. Zhu XH, Cheng J, Gao J. “Isolation of mouse THP gene promoter and demonstration of its kidney-specific activity in transgenic mice.” Am J Physiol Renal Physiol 2002 Apr; 282 (4): F608-F617
  9. Zhu XH, Shen YL, Jing YK. “Apoptosis and growth inhibition in malignant lymphocytes after treatment with Arsenic trioxide at clinically achievable concentrations.” Journal of the National Cancer Institute 1999 May; 91(9): 772-778
  10. Chen GX, Zhu XH, Meng XQ. “Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RAR and NPM-RAR (fusion genes).” Proc. Natl. Acad. Sci. USA 1999 May; 96 (11):6318-6323

View more at PubMed